Osteoarthritis is a major cause of disability and decreased quality of life in millions of patients and costs billions of dollars annually to treat. The current treatment options for osteoarthritis include weight loss, activity modification, anti-inflammatory medications, steroid intra-articular injections, lubricating hyaluronic acid injections and arthroplasty for end-stage cases. There has been interest in recent decades in identifying biological treatment modalities to slow the progression of the disease and preserve native joints. Biologics including platelet-rich plasma, bone marrow aspirate concentrate and adipose-derived mesenchymal stem cells are among the most commonly investigated treatments. Existing literature demonstrates anti-inflammatory properties of orthobiologics, butno treatment has clearly demonstrated significant joint preservation properties, including the ability to reverse progression of osteoarthritis. What is more clear is that these injection treatments have been shown in the majority of studies to be safe. Research is ongoing to identify optimal indications, preparations, compositions, safety profiles and clinical outcomes of biological therapies. This article will review the current evidence of biologics for treatment of osteoarthritis and recent statements made by orthopaedic subspecialty groups on this important topic.
- Cell therapy
Statistics from Altmetric.com
Contributors EJC, RMF and BM contributed to conception of the article, literature review, manuscript preparation and editing.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests RMF reports other from AAOS, other from American Orthopaedic Society for Sports Medicine, personal fees from Arthrex, other from Arthroscopy Association of North America, personal fees and other from Elsevier, other from the International Cartilage Regeneration & Joint Preservation Society and other from Orthopedics Today, outside the submitted work. BM reports other from AJSM, Cartilage, personal fees from Arthrex, other from Chairman CONCACAF Medical Committee, personal fees from DePuy, a Johnson & Johnson company, personal fees from Exactech, and other from Kerlan-Jobe Institute, outside the submitted work.
Patient consent for publication Not required.
Provenance and peer review Commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.